Indoco Remedies Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wier9l8h1hbvibugfyqcpy5n.pdf

Key Takeaways


The Three Headwinds That Defined FY25

Aditi Kare Panandikar: "Many of you have been partners with us through our many quarters of success, and I thank you to being patient with us through this quarter, which no doubt has been quite painful and for this entire year, which has been one of a kind for Indoco."

U.S. Business: A Tale of Two Plants


International Business: Capacity Waiting for Demand

Aditi Kare Panandikar: "I would like to wait for another quarter for numbers to talk for themselves because it's a dynamic between both. It is not sufficient for us to complete our restructuring of manufacturing. We also should be able to supply from those sites very effectively."

India Business: Outperforming in Covered Markets


Warren Remedies & the OTC Bet

Aditi Kare Panandikar: "The sensitivity market otherwise is INR500 crores, INR600 crore market. And the moment you go look at the sensitivity toothpaste market in Nielsen, it is an INR1,100 crore market. So it's a no-brainer that we had to go for this."

Cost Structure & Balance Sheet

Aditi Kare Panandikar: "I believe we are at the rock bottom of the losses. And from here on, I don't expect any further deterioration."

Guidance & Commitments

CommitmentSpecificsTimeline
Sterile plant supply resumptionIncremental effective sales from Plant II to beginQ2 FY26, with gradual pickup through Q4
Remediation completionMost updates to be completed; site ready for inspectionJuly or August 2025
Other expenses targetArrest at ₹120 cr per quarter (from ~₹140 cr)"In another quarter"
Europe revenue recoveryReturn to ~₹300 cr levelFY26
Warren Remedies breakevenSubsidiary reaches breakevenFY27
Debt trajectoryCurrent ~₹960 cr estimated as the peakNow
CapexOnly routine maintenance capex anticipatedFY26
R&D spendRemain around 5% of top lineOngoing

Key Metrics

MetricQ4 FY25
Consolidated net revenue₹383.9 cr, vs ₹439.1 cr in Q4 FY24
Standalone net revenue₹341.1 cr, vs ₹435.1 cr in Q4 FY24
Consolidated EBITDA marginminus 0.2% at minus ₹0.08 cr, vs 11.1% at ₹48.9 cr in Q4 FY24
Standalone EBITDA margin1% at ₹3.5 cr, vs 13.2% at ₹57.4 cr in Q4 FY24
Domestic formulation revenue₹185.1 cr, vs ₹191.1 cr in Q4 FY24
International formulation revenue₹110.4 cr, vs ₹214 cr in Q4 FY24
US business revenue₹30.8 cr, vs ₹67.5 cr in Q4 FY24
Europe business revenue₹46.6 cr, vs ₹76.5 cr in Q4 FY24
Emerging markets revenue₹31.8 cr, vs ₹68.2 cr in Q4 FY24
API business revenue₹40.9 cr, vs ₹21.7 cr in Q4 FY24
Services revenue (AnaCipher, Indoco Analytical)₹4.7 cr, vs ₹8.3 cr in Q4 FY24
Cylopam turnover (IQVIA, PTR rates)₹178 cr, added ₹25 cr incrementally in one year
Total consolidated debt~₹960 cr, management estimates this is the peak
Remediation expenses~₹4 cr per quarter, incurred all four quarters of FY25
R&D spend~5% of sales, management plans to maintain this level